Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
328.00
+2.36 (0.72%)
At close: Jul 24, 2025, 4:00 PM
329.00
+1.00 (0.30%)
After-hours: Jul 24, 2025, 6:17 PM EDT

Alnylam Pharmaceuticals Stock Forecast

Stock Price Forecast

The 25 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $347.75, which forecasts a 6.02% increase in the stock price over the next year. The lowest target is $220 and the highest is $500.

Price Target: $347.75 (+6.02%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$220$347.75$349$500
Change-32.93%+6.02%+6.40%+52.44%

Analyst Ratings

The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy101111121113
Buy899988
Hold433333
Sell111111
Strong Sell000000
Total232424252325

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Truist Securities
Truist Securities
Strong Buy
Initiates
$385
Strong BuyInitiates$385+17.38%Jul 21, 2025
JP Morgan
JP Morgan
Buy
Maintains
$338$348
BuyMaintains$338$348+6.10%Jul 16, 2025
Citigroup
Citigroup
Strong Buy
Maintains
$364$404
Strong BuyMaintains$364$404+23.17%Jul 11, 2025
B of A Securities
B of A Securities
Strong Buy
Maintains
$336$359
Strong BuyMaintains$336$359+9.45%Jul 11, 2025
Jefferies
Jefferies
Strong Buy
Maintains
$328$384
Strong BuyMaintains$328$384+17.07%Jul 7, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
2.98B
from 2.25B
Increased by 32.73%
Revenue Next Year
3.92B
from 2.98B
Increased by 31.50%
EPS This Year
-1.39
from -2.18
EPS Next Year
1.47
from -1.39
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
492.85M844.29M1.04B1.83B2.25B2.98B3.92B4.98B
Revenue Growth
124.28%71.31%22.88%76.24%22.97%32.73%31.50%26.81%
EPS
-7.46-7.20-9.30-3.52-2.18-1.391.476.36
EPS Growth
-------332.10%
Forward PE
------222.6951.54
No. Analysts
-----363527
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High3.6B5.9B6.9B
Avg3.0B3.9B5.0B
Low2.4B2.8B3.5B

Revenue Growth

Revenue Growth20252026202720282029
High
60.2%
97.8%
76.9%
Avg
32.7%
31.5%
26.8%
Low
7.9%
-7.6%
-10.1%

EPS Forecast

EPS20252026202720282029
High-0.455.5211.66
Avg-1.391.476.36
Low-2.29-3.111.48

EPS Growth

EPS Growth20252026202720282029
High--
691.3%
Avg--
332.1%
Low--
0.5%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.